Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Assessing the feasibility of nanopore clinical metagenomics in the context of the Coronavirus disease (COVID-19) pandemic

FY 2020-21

Summary
The COVID-19 pandemic and ensuing public health emergency that has highlighted the need for new rapid, cost-effective, and comprehensive viral screening techniques. The current RT-qPCR method, despite its relatively low-cost and reliability, still requires many hours of lab time and is only useful for detecting targeted pathogens. There is an urgent need to explore alternative diagnostic strategies to aid in the fight against COVID-19, as well as future pandemics. Metagenomic whole genome sequencing (MWGS) allows researchers to characterize all genetic material of a biospecimen, allowing the detection of multiple pathogens or co-infections not captured by standard diagnostic panels. This approach to testing can also assess the contribution of one or more pathogens to patient clinical outcomes. Sequencing technologies have been historically expensive and logistically challenging for diagnostic laboratories. However, the Oxford Nanopore Technologies (ONT) MinION device has reduced the cost and increased the portability and speed of MWGS, opening the door for future clinical applications. This project will optimize and assess the performance of a MWGS diagnostic assay using the ONT sequencing platform to detect SARS-CoV-2 and other viruses in oropharyngeal swab specimens. We will non selectively amplify viral RNA into cDNA to obtain sufficient genetic material for MWGS, an approach that has been applied previously to both influenza and SARS-CoV-2. Test performance metrics will be estimated. We will work with the Public Health Laboratory at the BCCDC to ensure technological and knowledge translation. This study will determine the feasibility and performance of clinical metagenomics as a diagnostic tool for viral infection in the context of the COVID-19 pandemic and beyond.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449723
Name
Gauthier Nicholas
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Assessing the feasibility of nanopore clinical metagenomics in the context of the Coronavirus disease (COVID-19) pandemic
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clinical; Infectious Diseases; Metagenomics; Microbiome; Next-Generation Sequencing; Virome
Abstract
The COVID-19 pandemic and ensuing public health emergency that has highlighted the need for new rapid, cost-effective, and comprehensive viral screening techniques. The current RT-qPCR method, despite its relatively low-cost and reliability, still requires many hours of lab time and is only useful for detecting targeted pathogens. There is an urgent need to explore alternative diagnostic strategies to aid in the fight against COVID-19, as well as future pandemics. Metagenomic whole genome sequencing (MWGS) allows researchers to characterize all genetic material of a biospecimen, allowing the detection of multiple pathogens or co-infections not captured by standard diagnostic panels. This approach to testing can also assess the contribution of one or more pathogens to patient clinical outcomes. Sequencing technologies have been historically expensive and logistically challenging for diagnostic laboratories. However, the Oxford Nanopore Technologies (ONT) MinION device has reduced the cost and increased the portability and speed of MWGS, opening the door for future clinical applications. This project will optimize and assess the performance of a MWGS diagnostic assay using the ONT sequencing platform to detect SARS-CoV-2 and other viruses in oropharyngeal swab specimens. We will non selectively amplify viral RNA into cDNA to obtain sufficient genetic material for MWGS, an approach that has been applied previously to both influenza and SARS-CoV-2. Test performance metrics will be estimated. We will work with the Public Health Laboratory at the BCCDC to ensure technological and knowledge translation. This study will determine the feasibility and performance of clinical metagenomics as a diagnostic tool for viral infection in the context of the COVID-19 pandemic and beyond.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gauthier, Nicholas
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~